DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Hepatitis
drugs for, 1609–1617
interferons for, 1609–1614
Hepatitis B virus infection, drugs for,
1614
Hepatitis C virus infection, drugs for,
1609–1614
Hepatocellular carcinoma (HCC),
1740, 1860
Hepatocytes, ABC transporters in, 108,
109f
Hepatotoxicity
of acetaminophen, 983
of angiotensin converting enzyme
inhibitors, 736
of niacin, 900
of statins, 896
Hepoxilins, 937, 946
HER1. See Epidermal growth factor
receptor(s) (EGFR)
Herbal extracts, for menopausal
symptoms, 1840
HERCEPTIN (trastuzumab), 1737
Hereditary hemochromatosis, 102t
HER2/neu inhibitors, 1737–1738
Herpes simplex virus (HSV)
drugs for, 1598–1599
iridocyclitis, 1783t
keratoconjunctivitis, 1783t
skin infection, 1818
Herpesviruses, treatment of,
1593–1605
Herpes zoster ophthalmicus, 1783t
HERPLEX (idoxuridine), 1596t
HERRRICK LACRIMAL PLUG, 1779
Heterodimerization, 487
Heterophyes heterophyes, 1449
Heterozygotes, 147
HETEs, 938f, 939–941, 940f
Hexachlorocyclohexane. See Lindane
Hexamethonium (C6), 273f
Hexamethylmelamine, 1668t–1670t
Hexobarbital, polymorphisms and
response to, 159t
HGPRT. See Hypoxanthine guanine
phosphoribosyl transferase
(HGPRT)
HGVbase. See Human Genome
Variation Database
(HGVbase)
Hidradenitis suppurativa
retinoids for, 1811
treatment of, 1816
HIF. See Hypoxia-inducible factor
(HIF)
High-altitude illness, 681
High-density lipoproteins (HDL), 877,
883–884
characteristics of, 879t
gemfibrozil and, 902
low, treatment of, 892
nicotinic acid and, 900
plasma level, and risk for coronary
heart disease, 887t
plasma levels, classification of, 887t
statins and, 894
High-flow oxygen administration,
559–560
High-throughput screening, in drug
development, 4
Hippocampus, alpha adrenergic
receptors in, 203t
Hirsutism, 1840–1841
Hirudin, therapeutic uses of, in
myocardial ischemia, 771
His-Purkinje system
acetylcholine and, 221
in autonomic nervous system, 178t
Histamine, 911–918, 1815
in central nervous system, 384–388
in inflammation, 960
itching caused by, 918
and mast cell proliferation, 915
mechanism of action of, 915–916
metabolism of, 912–913, 912f
neuromuscular blocking agents and,
262–263
pain caused by, 918
pharmacology of, 915–918
receptors, 1815
antagonists (See Antihistamines)
antipsychotics and, 427t
chemistry of, 912
H 1
, 427t
antidepressant potencies at,
410t
in skin mast cells, 1815
regulation of mediator release and,
914
release, histamine receptor-effector
coupling and, 916
release of, 914–915
by drugs, peptides, and venoms,
914
mechanism of, 914–915
storage of, 912–913
structure of, 912f
synthesis of, 912–913, 912f
toxicity, 916
and triple response of Lewis, 917
Histamine (Cont.):
and vasodilation, 916–917
and vasopressin secretion, 704
Histamine H 1
receptor agonists, 912,
912f, 916
structure of, 912f
Histamine H 2
receptor agonists, 912,
912f, 916
structure of, 912f
Histamine H 3
receptor agonists,
911–912, 912f
structure of, 912f
Histamine H 4
receptor agonists, 912,
912f, 916
Histamine H 1
receptor antagonists,
911, 916, 918–924,
921t–922t
absorption of, 920
adverse effects and side effects of,
923
and allergy, 919
allergy to, 923
and anaphylaxis, 919
anticholinergic effects of, 920
anti-pruritic effects, 1815–1816
and capillary permeability, 918
and central nervous system,
919–920
chemistry, 918
clinical summary, 925–926
distribution of, 920
dosage of, 921t
duration of action of, 921t
excretion of, 920
and exocrine glands, 919
first-generation, 1816
pharmacokinetics of, 1816t
and flare, 919
geriatric use, 923
history of, 918
and hypersensitivity reactions, 919
and itch, 919
local anesthetic effect, 920
mechanism of action of, 918
pediatric use, 923
pharmacological properties of,
918–920
poisoning with, 923
preparations of, 921t
second-generation, 920, 1816
pharmacokinetics of, 1816t
sedation caused by, 920
side effects of, 920
and smooth muscle, 918
structure-activity relationship, 918
2033
INDEX